ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$59.20 USD
+0.25 (0.42%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.20 USD
+0.25 (0.42%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth A Momentum A VGM
Zacks News
ANI Pharmaceuticals (ANIP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $51.30, marking a +0.33% move from the previous day.
Ensign Group (ENSG) Up 26% in a Year: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) is well-poised for growth on the back of an aging U.S. population, an expanding healthcare portfolio and prudent deployment of capital.
GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.
Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy
by Zacks Equity Research
Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.
Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs
by Zacks Equity Research
Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.
DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly
by Zacks Equity Research
DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business
by Zacks Equity Research
AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.
2seventy (TSVT) Down 9% on Patient Death in Leukemia Study
by Zacks Equity Research
Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.
Humana (HUM) Wins Contract to Serve Oklahoma's Medicaid Members
by Zacks Equity Research
Humana (HUM) secures a contract from the OHCA and is likely to provide improved health outcomes for Medicaid members of Oklahoma.
Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
by Zacks Equity Research
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
Tenet Healthcare (THC) Gains 42.1% YTD: More Room to Run?
by Zacks Equity Research
Tenet Healthcare's (THC) aim to boost USPI's network through continuous buyouts is positioning the company well for growth.
Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%
by Zacks Equity Research
Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.
Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review
by Zacks Equity Research
The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.
Factors That Make Ensign Group (ENSG) a Lucrative Bet Now
by Zacks Equity Research
Ensign Group (ENSG) is well-poised for growth on increasing service revenues, an expanding healthcare portfolio and a strong capital position.
Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Membership growth, expanding government business and improving operating margin poise UnitedHealth Group (UNH) well for growth.
PTC Therapeutics' (PTCT) Rare Disease Drug Fails in Study
by Zacks Equity Research
PTC Therapeutics' (PTCT) vatiquinone did not achieve its primary endpoint in a late-stage study in treating Friedreich Ataxia patients. Shares decline 21% post the news.
Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy
by Zacks Equity Research
Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.
PTC Therapeutics' (PTCT) PKU Drug Meets Study Goal, Up 7.6%
by Zacks Equity Research
Data from a late-stage study data shows that treatment with PTC Therapeutics' (PTCT) sepiapterin led to a significant reduction in Phe levels in PKU patients. Post the news, share price rises.
Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data
by Zacks Equity Research
A mid-stage study data shows that Immutep's (IMMP) lead candidate as a combination therapy in first-line NSCLC achieved better-than-expected overall survival results.
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Compugen (CGEN) have performed compared to their sector so far this year.
FTC Challenges Amgen's (AMGN) $28B Acquisition of Horizon
by Zacks Equity Research
Per the FTC, Amgen's (AMGN) acquisition of Horizon (HZNP) would entrench the monopoly positions for the latter's medications for thyroid eye disease and chronic refractory gout.
HCA Healthcare (HCA) Gains 29% in a Year: More Upside Left?
by Zacks Equity Research
HCA Healthcare (HCA) is well-poised for growth on the back of higher revenues, a diversified treatment network and sound operating cash flows.